Bordetella bronchiseptica and toxigenic type D Pasteurella multocida as agents of severe atrophic rhinitis of swine

Rhodes, Marvin B.; New, C.W.; Baker, P.K.; Hogg, Alex; Underdahl, Norman R.

doi:10.1016/0378-1135(87)90043-5

Cited by 14 publications

(10 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various vaccines containing bacterin and/or toxoid of B. bronchiseptica and DNT-producing serotype D P. multocida are being used worldwide, but these vaccines have been evaluated against experimental AR with B. bronchiseptica and DNT-producing serotype D P. multocida [1,14,24,36]. In the present study, piglets were challenged with B. bronchiseptica and DNT-producing serotype A P. multocida, and consequently all of non-vaccinated group showed severe or moderate nasal turbinate atrophy at slaughter, which has been described in reports on inoculation with B. bronchiseptica and toxigenic P. multocida serotype D [23,[27][28][29]32], but none of the pigs showed signs of AR. It was considered that the experimental period was too short for the development of clinical signs of AR in these pigs.…”

supporting

confidence: 58%

Effect of Bordetella bronchiseptica and Serotype D Pasteurella multocida Bacterin-Toxoid on the Occurrence of Atrophic Rhinitis after Experimental Infection with B. bronchiseptica and Toxigenic Type A P. multocida.

Sakano

Okada²,

Taneda³

et al. 1997

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. In efficacy tests, 7 primary specific-pathogen-free piglets vaccinated with the Bordetella bronchiseptica and type D Pasteurella multocida bacterin-toxoid were challenged with B. bronchiseptica and type A P. multocida. Severe or moderate nasal turbinate atrophy was produced in the non-vaccinated pigs, whereas, only one of the 4 pigs in the vaccinated group had slight turbinate atrophy. Other immune sera against crude toxin of P. multocida type A or D were cross neutralized. bronchiseptica was done in a 0.5 ml suspension instilled into each nostril on the post-vaccination week (PVW) 4, and P. multocida was done in the same manner as with B. bronchiseptica starting from PVW 5 for four consecutive days. The pigs were observed daily for clinical signs of AR. Nasal swab samples were taken from all pigs immediately before vaccination and at regular time intervals after vaccination. For the recovery of B. bronchiseptica, samples were plated on MacConkey agar (Eiken Chemical Co., Ltd., Tokyo) containing 25 µg/ml of furazolidone, 0.5 µg/ml gentamicin, 4 µg/ml of fradiomycin and 2 µg/ml of clindamycin, and were incubated for 3 days at 37°C. The samples were also cultured for P. multocida using DS agar (Difco Lab.) containing 0.1 µg/ml gentamicin and 30 µg/ml vancomycin for 18 hr at 37°C. Suspected colonies of B. bronchiseptica or P. multocida were identified using conventional biochemical tests [6,21]. Blood samples were collected from pigs at the same times as the nasal swab samples were taken. ELISA tests for the detection of antibodies against pure DNT of B. bronchiseptica [8,9] and pure DNT of P. multocida serotype D [18] were performed. Each pure DNT antigen showed a single band of nearly 160 kd or 140 kd by sodium dodecyl sulfate-polyacrylamide disc gel electrophoresis. The pigs were sacrificed using an intravenous injection of thiopental sodium (Tanabe Pharmaceutical Co., Osaka) on PVW 7. The snouts were cut transversely between the first molar and the canine tooth, and the turbinate atrophy was recorded as: = normal, + = slight, ++ = moderate and +++ = severe according to the criteria described by Maeda et al. [15].The relationship between clinical atrophic rhinitis (AR) of swine and infections with Bordetella bronchiseptica and/ or toxigenic capsular serotype D Pasteurella multocida has been reported by many investigators [2, 3, 23, 27-30, 32, 35]. In addition, it has been reported that capsular serotype A P. multocida is isolated predominantly from pneumonic lung in swine [26,37]. Previous experiments have shown that the dermonecrotic toxin (DNT) of B. bronchiseptica and P. multocida are virulence factors producing AR [7,11,12]. Therefore, the bacterin and/or toxoid [22] containing B. bronchiseptica and toxigenic capsular serotype D P. multocida were developed, and these vaccines were prophylactic against experimental AR with B. bronchiseptica and toxigenic capsular serotype D P. multocida [1,14,24,36]. Although there is little information about toxigenic capsular serotype A P. multocida associated wi...

show abstract

supporting

confidence: 58%

Effect of Bordetella bronchiseptica and Serotype D Pasteurella multocida Bacterin-Toxoid on the Occurrence of Atrophic Rhinitis after Experimental Infection with B. bronchiseptica and Toxigenic Type A P. multocida.

Sakano

Okada²,

Taneda³

et al. 1997

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

show abstract

“…Preexisting or coinfection with other respiratory pathogens, particularly Bordetella bronchiseptica (149,150,(175)(176)(177)(178)(179)(180) or Mannheimia haemolytica (147), significantly enhances colonization by P. multocida, leading to more severe disease. Interestingly, a recent report showed that P. multocida inhibits the growth of M. haemolytica in vitro (181).…”

Section: Pasteurella Disease In Animals Pasteurellosis Prevalencementioning

confidence: 99%

Pasteurella multocida: from Zoonosis to Cellular Microbiology

2013

View full text Add to dashboard Cite

SUMMARY In a world where most emerging and reemerging infectious diseases are zoonotic in nature and our contacts with both domestic and wild animals abound, there is growing awareness of the potential for human acquisition of animal diseases. Like other Pasteurellaceae , Pasteurella species are highly prevalent among animal populations, where they are often found as part of the normal microbiota of the oral, nasopharyngeal, and upper respiratory tracts. Many Pasteurella species are opportunistic pathogens that can cause endemic disease and are associated increasingly with epizootic outbreaks. Zoonotic transmission to humans usually occurs through animal bites or contact with nasal secretions, with P. multocida being the most prevalent isolate observed in human infections. Here we review recent comparative genomics and molecular pathogenesis studies that have advanced our understanding of the multiple virulence mechanisms employed by Pasteurella species to establish acute and chronic infections. We also summarize efforts being explored to enhance our ability to rapidly and accurately identify and distinguish among clinical isolates and to control pasteurellosis by improved development of new vaccines and treatment regimens.

show abstract

“…Inoculated the Bordetella bronchiseptica and Pasteurella multocida at the same time used in group 2 had been tested in 6-day-old, 3-week-old, and 6 to 8-week-old piglets with varying degrees of turbinate lesions [8][9][10]. However, there is no report on the effect of above two kinds of challenge models.…”

Section: Discussionmentioning

confidence: 99%

“…One model is to treat with Bordetella bronchiseptica followed by Toxigenic Pasteurella multocida infection [2][3][4][5][6][7]. Another model is to inoculate with Bordetella bronchiseptica and Pasteurella multocida at the same time [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Comparison of Two Challenge Models of Atrophic Rhinitis in Piglets

Gu¹,

Fan²,

Hu³

et al. 2017

J Vaccines Vaccin

View full text Add to dashboard Cite

Background: Swine atrophic rhinitis (AR) is a multiple chronic respiratory diseasemainly caused by porcine Bordetella bronchiseptica (Bb) and Toxigenic Pasteurella multocida (T + Pm). There are two challenge models using Bordetella bronchiseptica and Pasteurella multocida. The first model is to treat pigs with Bordetella bronchiseptica followed by Toxigenic Pasteurella multocida infection. Another model is to inoculate pigs with Bordetella bronchiseptica and Pasteurella multocida simultaneously. So far, there is no report about comparison of these two challenge models as for their effectiveness to establish infection.

show abstract

Bordetella bronchiseptica and toxigenic type D Pasteurella multocida as agents of severe atrophic rhinitis of swine

Cited by 14 publications

References 2 publications

Effect of Bordetella bronchiseptica and Serotype D Pasteurella multocida Bacterin-Toxoid on the Occurrence of Atrophic Rhinitis after Experimental Infection with B. bronchiseptica and Toxigenic Type A P. multocida.

Effect of Bordetella bronchiseptica and Serotype D Pasteurella multocida Bacterin-Toxoid on the Occurrence of Atrophic Rhinitis after Experimental Infection with B. bronchiseptica and Toxigenic Type A P. multocida.

Pasteurella multocida: from Zoonosis to Cellular Microbiology

Comparison of Two Challenge Models of Atrophic Rhinitis in Piglets

Contact Info

Product

Resources

About